Peptide and Oligonucleotide CDMO Trends and Forecast
The future of the global peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets. The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030 with a CAGR of 11.3% from 2024 to 2030. The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.Peptide and Oligonucleotide CDMO by Segment
The study includes a forecast for the global peptide and oligonucleotide CDMO by product, service type, end use, and region.Peptide and Oligonucleotide CDMO Market by Product [Shipment Analysis by Value from 2018 to 2030]:
- Peptides
- Oligonucleotides
Peptide and Oligonucleotide CDMO Market by Service Type [Shipment Analysis by Value from 2018 to 2030]:
- Contract Development
- Contract Manufacturing
Peptide and Oligonucleotide CDMO Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
- Pharmaceutical Companies
- Biopharmaceutical Companies
- Others
Peptide and Oligonucleotide CDMO Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Peptide and Oligonucleotide CDMO Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies peptide and oligonucleotide CDMO companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base.Some of the peptide and oligonucleotide CDMO companies profiled in this report include:
- PolyPeptide Group
- STA Pharmaceutical
- Bachem
- Creative Peptides
- Aurigene Pharmaceutical Services
- Merck
- EUROAPI
- Curia Global
- CordenPharm
- Sylentis
Peptide and Oligonucleotide CDMO Market Insights
The publisher forecasts that peptide will remain larger segment over the forecast period.Within this market, biopharmaceutical company will remain larger segment over the forecast period.
North America will remain the largest region over the forecast period.
Features of the Global Peptide and Oligonucleotide CDMO Market
- Market Size Estimates: Peptide and oligonucleotide CDMO market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Peptide and oligonucleotide CDMO market size by product, service type, end use, and region in terms of value ($B).
- Regional Analysis: Peptide and oligonucleotide CDMO market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different products, service types, end uses, and regions for the peptide and oligonucleotide CDMO market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the peptide and oligonucleotide CDMO market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the peptide and oligonucleotide CDMO market size?Answer: The global peptide and oligonucleotide CDMO market is expected to reach an estimated $5.0 billion by 2030.
Q2. What is the growth forecast for peptide and oligonucleotide CDMO market?
Answer: The global peptide and oligonucleotide CDMO market is expected to grow with a CAGR of 11.3% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the peptide and oligonucleotide CDMO market?
Answer: The major drivers for this market are growing popularity of customized medicine, increasing concern towards uncommon diseases, and rise in emphasis on peptide antivirals.
Q4. What are the major segments for peptide and oligonucleotide CDMO market?
Answer: The future of the peptide and oligonucleotide CDMO market looks promising with opportunities in the pharmaceutical company and biopharmaceutical company markets.
Q5. Who are the key peptide and oligonucleotide CDMO market companies?
Answer: Some of the key peptide and oligonucleotide CDMO companies are as follows:
- PolyPeptide Group
- STA Pharmaceutical
- Bachem
- Creative Peptides
- Aurigene Pharmaceutical Services
- Merck
- EUROAPI
- Curia Global
- CordenPharm
- Sylentis
Answer: The publisher forecasts that peptide will remain larger segment over the forecast period.
Q7. In peptide and oligonucleotide CDMO market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period.
Q.8 Do we receive customization in this report?
Answer: Yes, the publisher provides 10% customization without any additional cost.
This report answers the following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the peptide and oligonucleotide CDMO market by product (peptides and oligonucleotides), service type (contract development and contract manufacturing), end use (pharmaceutical companies, biopharmaceutical companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Peptide and Oligonucleotide CDMO Market : Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned
- PolyPeptide Group
- STA Pharmaceutical
- Bachem
- Creative Peptides
- Aurigene Pharmaceutical Services
- Merck
- EUROAPI
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
